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Abstract
Background—Hepatitis C virus (HCV) remains a major contributor to morbidity and mortality 
worldwide. Since 2009, Kentucky has led the United States in cases of acute HCV, driven largely 
by injection drug use in rural areas. Improved treatment regimens hold promise of mitigating the 
impact and transmission of HCV, but numerous barriers obstruct people who inject drugs (PWID) 
from receiving care, particularly in medically underserved settings.
Methods—503 rural people who use drugs were recruited using respondent-driven sampling and 
received HCV screening and post-test counseling. Presence of HCV antibodies was assessed using 
enzyme immunoassay of dried blood samples. Sociodemographic and behavioral data were 
collected using computer-based questionnaires. Predictors of contacting a healthcare provider for 
follow-up following HCV-positive serotest and counseling were determined using discrete-time 
survival analysis.
Results—150 (59%) of 254 participants reported contacting a healthcare provider within 18 
months of positive serotest and counseling; the highest probability occurred within six months of 
serotesting. 35 participants (14%) reported they were seeking treatment, and 21 (8%) reported 
receiving treatment. In multivariate time-dependent modeling, health insurance, internet access, 
prior substance use treatment, meeting DSM-IV criteria for generalized anxiety disorder, and 
recent marijuana use increased the odds of making contact for follow-up. Participants meeting 
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criteria for major depressive disorder and reporting prior methadone use, whether legal or illegal, 
were less likely to contact a provider.
Conclusion—While only 8% received treatment after HCV-positive screening, contacting a 
healthcare provider was frequent in this sample of rural PWID, suggesting that the major barriers 
to care are likely further downstream. These findings offer insight into the determinants of 
engaging the cascade of medical treatment for HCV and ultimately, treatment-as-prevention. 
Further study and increased resources to support integrated interventions with effectiveness in 
other settings are recommended to mitigate the impact of HCV in this resource-deprived setting.
Keywords
Hepatitis C; drug injection; treatment; rural
Introduction
Hepatitis C virus (HCV) remains a major public health problem worldwide, causing over 
500,000 deaths per year (Lim et al., 2012) and greater mortality in the United States than 
that attributed to HIV (Ly et al., 2012). The virus is hyper-endemic worldwide among people 
who inject drugs (PWID), with 73% median seroprevalence among individuals who have 
ever injected and transmission typically occurring via sharing of needles, syringes, and drug-
preparation equipment (Nelson et al., 2011). Unfortunately, medical evaluation to assess for 
disease progression and treatment eligibility occurs sporadically among seropositive 
individuals in the general population (Spradling et al., 2014) and even less frequently among 
PWID (Wiessing et al., 2014). Fortunately, remarkable advances in pharmacotherapy now 
offer greater than 90% efficacy for most genotypes, tremendously decreased adverse effect 
profiles, and shortened interferon- and ribavirin-free regimens (Li & De Clercq, 2017; 
Rehermann, 2016), and it has been shown that PWID in community clinics and opioid 
substitution programs can achieve rates of sustained virologic response (SVR) equivalent to 
non-injectors even with older regimens including interferon and ribavirin (Grebely et al., 
2016; Grebely et al., 2015). For these reasons, identifying factors associated with seeking 
and receiving HCV-related medical care after seropositive test and post-test risk-reduction 
counseling (T&C) is critical in underserved and often stigmatized populations such as PWID 
(Grebely et al., 2008).
In prior research, PWID-specific barriers to HCV-related medical care have included lack of 
status awareness and HCV-related knowledge, homelessness and unstable lifestyle, lack of 
social support, psychiatric comorbidity, HIV co-infection, fear of diagnosis and medical 
procedures, concerns regarding drug toxicity and low efficacy, and lack of transportation 
(Mravcik et al., 2013). Stoove et al. (2005) reported that patients with no history of IDU 
were greater than threefold more likely to be referred to an HCV specialist than PWID, and 
current injectors were significantly less likely to initiate treatment, underlining substantial 
impact of IDU status on HCV-related care (Stoove, Gifford, & Dore, 2005). Similarly, 
despite 81% being interested in receiving treatment, just 27% of PWID in three U.S. cities 
received medical evaluation HCV-positive serotesting (Strathdee et al., 2005). In another 
study of urban PWID, just 14% and 6% reported receiving medical evaluation for HCV and 
initiating treatment, respectively; barriers to treatment included perceptions of severe 
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adverse effects, low efficacy, and deprioritization due to lack of symptoms (Mehta et al., 
2008). Grebely et al. (2009) found only 15 of 1360 seropositive Canadian PWID had 
initiated treatment, among whom only four completed treatment and three achieved 
sustained virologic response. Strikingly, HCV seroconversion occurred at 25 times the rate 
of HCV treatment (Grebely et al., 2009). However, when referral to medical care was 
coupled with seropositive T&C, medical evaluation occurred in 76% of PWID, and 
guideline-based clinical criteria became the major determinant of treatment initiation 
(Grebely et al., 2010). Finally, of particular relevance to rural PWID, shorter travel distance 
to clinics (Monnet et al., 2008) and increasing community size (Astell-Burt, Flowerdew, 
Boyle, & Dillon, 2011) have been positively associated with HCV-related medical care.
Identifying predictors of both seeking and engaging in HCV-related medical care after T&C 
is central to enhancing public health interventions among PWID, especially with regard to 
the utility of HCV “treatment as prevention” (Grebely & Dore, 2014; Martin et al., 2013). 
Such efforts are particularly relevant in medically underserved rural areas such as the 
Central Appalachian region of the United States, where harm reduction, substance use 
disorder (SUD), and integrated treatment programs recommended to address widespread 
HCV among PWID (Birkhead et al., 2007; Grebely et al., 2010) are largely unavailable 
(Appalachian Regional Commission, 2008; Des Jarlais et al., 2015; Stensland J, 2002). 
Although a March 2015 Kentucky law permitted syringe exchange programs (SEPs) and 
expanded access to naloxone and other harm reduction services, as of February 2017 only 8 
of 54 Appalachian Kentucky counties had established operational SEPs (Department for 
Public Health, 2015). PWID also encounter barriers to accessing syringes in local 
pharmacies, as Kentucky law requires that persons engaged in sales of syringes collect 
detailed information about individuals purchasing syringes, including information on the 
planned use of such syringes (Kentucky Legislative Research Commission, 2005). By 
contrast, such programs are often more accessible to PWID in major urban areas and/or in 
countries with comprehensive HCV public health programs, where the majority of prior 
research on HCV-related healthcare engagement among PWID has occurred.
As yet there is no clear consensus regarding factors likely to increase seeking and 
engagement in HCV-related care, and previously reported characteristics may be highly 
population- and context-specific. Moreover, little is known regarding rural PWID, who may 
differ significantly from their urban and suburban counterparts (Havens et al., 2013) and are 
thought to be in large part driving surging resurgent HCV incidence observed in the United 
States in recent years (Zibbell et al., 2015). In the United States, Kentucky has reported the 
highest incidence of acute HCV since 2009 (Centers for Disease Control and Prevention, 
2016). For these reasons, this study identifies predictors of contacting a healthcare provider 
for recommended follow-up and describes the uptake of treatment following HCV-
seropositive T&C in a medically underserved population of people who use and inject drugs 
in rural Appalachian Kentucky.
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Methods
Design and sampling
Data were collected during the cohort study Social Networks among Appalachian People 
with an overall aim of identifying risk factors for transmission of infectious diseases 
including HCV, HIV, and herpes simplex virus type 2 among people who use drugs in the 
rural Central Appalachian region of eastern Kentucky, USA. As described previously 
(Havens et al., 2013), 503 participants were recruited from November 2008 to August 2010 
using respondent-driven sampling (RDS) (Heckathorn, 1997), with data collected during the 
18-month wave until February 2012. Eligible participants were 18 years or older, 
community-dwelling, and had used heroin, crack/cocaine, methamphetamine, prescription 
opioids non-medically within the last six months. Participants with a positive HCV serum 
antibody test at study enrollment, six-month, or twelve-month follow-up and receiving test 
results and counseling at least 30 days prior to subsequent interviewing were included in this 
analysis. All participants gave informed consent and were compensated $50 USD for each 
study visit. Study procedures were approved by the University of Kentucky Institutional 
Review Board, and a Certificate of Confidentiality was obtained from NIH.
Data collection
HCV screening was completed at each study visit using the Home Access® Hepatitis C 
Check serum antibody test with standard pre-test counseling given to all participants. This 
test utilizes dried blood spot specimens obtained by finger-stick and third-generation 
enzyme immunoassay to detect HCV serum antibodies; sensitivity and specificity are 98.2% 
and 99.6%, respectively (US Food and Drug Administration, 1999). Post-test counseling was 
tailored to test results with standard messages including advising seropositive participants to 
seek medical evaluation for HCV from a healthcare provider and avoid alcohol intake as 
recommended by CDC (Centers for Disease Control and Prevention, 1998; Smith et al., 
2012), and to refrain from sharing syringes and other IDU-related equipment (AASLD-
IDSA, 2016), along with information regarding local options to obtain appropriate follow-up 
medical care.
The primary outcome variable was self-reported contact of a healthcare provider for medical 
follow-up receipt of seropositive T&C during the study, assessed via the following question: 
“After testing positive for hepatitis C did you contact a health professional to obtain follow-
up testing?” Self-reported seeking and receiving treatment for HCV was also collected, with 
the following questions for the former item: “Did you seek treatment for hepatitis C?” 
Sociodemographic and behavioral data were collected via interviewer-administered 
questionnaires using computer-assisting personal interviewing software, as described 
elsewhere (Havens et al., 2013), along with participant responses to the MINI 
neuropsychiatric interview version 5.0.31 (Sheehan et al., 1998), assessing for symptoms of 
major depressive disorder (MDD), generalized anxiety disorder (GAD), post-traumatic 
stress disorder, and antisocial personality disorder utilizing Diagnostic and Statistical 
Manual of Mental Disorders, 4th Edition (DSM-IV-TR) criteria. Lifetime and past six-
month illicit and non-medical prescription drug use was asked at each interview, along with 
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recent and lifetime alcohol and legal methadone and buprenorphine use, SUD treatment, 
drug overdose, and incarceration.
Shortest driving distance from participant address to Appalachian Regional Health Center 
(Hazard, KY), an inpatient and outpatient facility offering specialist HCV care centrally 
location to the five rural counties (>90% from Perry County, KY) sampled in this study and 
identified in post-test counseling materials provided to participants, was calculated at each 
visit using geocoded North American Street Map data (Environmental Systems Research 
Institute, 2010) and the Network Analyst tool in ArcGIS, version 10.2 (Redlands, CA). 
Participants who moved from the area after recruitment (n=10) were excluded from analysis 
of this measure. Possession of a driver’s license and access to a vehicle was asked at study 
enrollment to assess availability of transportation. HCV knowledge was assessed using six 
true/false questions including awareness of HCV treatment, as was knowledge of HCV-
positive status prior to study enrollment. Finally, number of individuals in each participant’s 
social support network was calculated from social network data at each interview, as 
described elsewhere (Young, Jonas, & Havens, 2013). Participants reported “alters” from 
whom they received social support in the form of food, money, or emotional assistance; the 
total number of “alters” named as providers of social support is hereafter referred to as 
“social support network out-degree” and was calculated for each study visit.
Statistical analysis
Longitudinal bivariate odds ratios were calculated in discrete time, controlling for the main 
effect of time and adjusted with sampling weights to correct for potential bias introduced by 
non-random sampling using RDSAT version 7.1 (Ithaca, NY) (Heckathorn, 1997; Volz et al., 
2012). Time-varying measures were lagged by one study interval, with independent 
variables significant at p<0.10 considered for inclusion in a multivariate model. 
Sociodemographic measures (sex, race, age, education, and income) were considered for 
inclusion in the multivariate model and retained in the final model if inclusion impacted 
other independent measures by ≥10% (Hosmer & Lemeshow, 1989). The following 
previously reported factors impacting access to HCV care in PWID were also considered in 
the final model: HCV-positive serostatus awareness, IDU or SUD treatment within the past 
six months, opioid substitution therapy (OST) reported as legally prescribed use of either 
methadone or buprenorphine, and the DSM-IV psychiatric measures described above.
Bivariate and multivariate analyses were conducted using discrete-time survival analysis 
(DTSA) (Allison, 1982; Singer & Willett, 1993, 2003), which utilizes a discrete-time hazard 
function depicting a set of probabilities observed during each time interval for interval-
censored dependent measures (Singer & Willett, 1993). For this analysis, more parsimonious 
approximations of the main effect of time (constant and linear approximations) were 
compared to the discrete-time model in a hierarchical manner utilizing goodness-of-fit 
testing p<0.05 level of significance. Nested parameterizations for time not differing 
significantly from the discrete model were considered, and independent measures were 
assessed using a hierarchical forward-selection process utilizing maximum-likelihood-based 
Wald testing with a chi-squared distribution and significance level of p<0.05 for potential 
covariates and the Bayesian information criterion (BIC) to differentiate between candidate 
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models. As DTSA assumes proportional odds across time for each predictor (Singer & 
Willett, 2003), independent measures in the final model were assessed for interactions with 
time at p<0.05 level of significance.
Results
N=254 of 503 baseline sample (50.5%) received HCV-seropositive T&C at enrollment 
(n0=226), six months (n6=21), and twelve months (n12=8); one participant not returning for 
interviewing following initial study visit was excluded. Table 1 summarizes sample 
proportions and RDS-adjusted population estimates of HCV-related healthcare events 
reported at any study visit. 150 participants (59.1%) reported contacting a healthcare 
provider for follow-up after receiving positive T&C, representing an estimated 51.8% of the 
sampled population. Of these 150 individuals, 35 (13.8%) described themselves as seeking 
treatment (12.4% population estimate), and 21 (8.3% of sample; 7.8% population estimate) 
reported receiving treatment for HCV. 31 participants were lost to follow-up, and the average 
number of follow-up visits for the sample was 1.9. Although the data describing where 
participants sought treatment were incomplete, most reported receiving follow-up testing 
and/or treatment through primary care providers, followed by community health centers 
(data not shown).
As summarized in Table 2, study participants were predominantly male (60%), white (95%), 
and single (76%), with a mean age of 33 years. 95% reported lifetime history of IDU, and 
98% reported ever having used OxyContin® non-medically, whereas 94% and 95% reported 
use of sedatives and cocaine, respectively. 87% had been incarcerated, and 28% reported 
history of drug overdose. 80 participants (32%) reported having any form of health 
insurance and 42 (17%) received SUD treatment during data collection; of note, there were 
no HIV-positive participants through twelve-month screening. Bivariate estimates of 
association with contacting a healthcare provider are summarized in table 2.
Table 3a depicts the conditional probability of contacting a healthcare provider after T&C: 
hazard was greatest in the six months immediately following HCV-positive T&C (0.38), 
with uniformly lower values after twelve (0.23) and eighteen months (0.23). As shown in 
table 3b, RDS-adjusted population estimates for probability of contacting a provider for 
follow-up decreased after the six-month study visit (0.37) to lower values at 12-month (0.18) 
and 18-month (0.16) study visits. The linear model for the main effect of time was selected 
for final multivariate modeling as it did not differ significantly from the fully discrete model 
(p=0.68). Hazard functions for the fully discrete model and linear time approximation are 
depicted in Figure 1.
The final multivariate model with independent predictors of contacting a provider for 
follow-up is presented in Table 4. No significant interactions with time were detected among 
independent covariates, supporting the proportional odds assumption. The main effect of 
time independently predicted 40% decreased odds of contacting a provider for each 6-month 
study interval elapsed since T&C (adjusted OR [aOR]=0.6). Having any form of health 
insurance more than doubled the odds of contacting a provider during the respective study 
interval (aOR=2.1), and meeting criteria for generalized anxiety disorder exhibited a similar 
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strong positive association (aOR=2.6). By contrast, meeting criteria for major depressive 
disorder halved the odds of contacting a provider (aOR=0.5), and two methadone-related 
measures decreased the odds of contacting a provider: recent legal use (aOR=0.2) and 
lifetime illegal use (aOR=0.3). By contrast, recent marijuana use was associated with 
increased odds of making contact for medical follow-up (aOR=1.7). Finally, awareness of 
prior HCV-positive testing did not significantly increase odds of the primary outcome 
(aOR=1.7; p<0.10) but was retained in the model given improved goodness-of-fit suggested 
by BIC relative to the reduced model.
Discussion
In this study of predictors of HCV-related medical care-seeking and treatment uptake, nearly 
60% of rural participants who use drugs contacted a healthcare provider for follow-up 
evaluation as recommended after seropositive T&C. Proportions of participants reporting 
they sought (<15%) and received treatment (<10%) were markedly lower. Other studies of 
PWID sampled from cities in the United States have reported markedly lower proportions of 
individuals undergoing medical evaluation following HCV+ serotesting, typically in the 
range of 21% (Mehta et al., 2008) to 27% (Strathdee et al., 2005), although few researchers 
have specifically examined the initial step of medical follow-up (i.e., contacting a healthcare 
provider to make an appointment). These proportions contrast with studies of HCV-
seropositive individuals receiving medical evaluation in other settings: for instance, 75% of 
Australian PWID receiving OST (Treloar, Hull, Dore, & Grebely, 2012) and 57% of a U.S. 
clinic-based sample (Spradling et al., 2014). Another study of 245 seropositive patients from 
the New York City health department reported that 67% obtained RNA testing when referred 
directly to medical services after T&C (McGibbon, Bornschlegel, & Balter, 2013), whereas 
53% of PWID received medical evaluation in data reported by Grebely and colleagues 
(2010) when healthcare referral was offered reflexively after T&C. In the latter study, 
clinical criteria based on published guidelines emerged as the primary determinant of HCV 
treatment initiation (Grebely et al., 2010).
While the proportion making contact to arrange medical follow-up for HCV in this rural 
sample was relatively high, the proportion describing themselves as seeking treatment in 
particular lagged in comparison. However, the 8% ultimately receiving treatment is 
comparable to other studies, which have typically ranged from 3% to 10% (Cullen, Stanley, 
Langton, Kelly, & Bury, 2007; Mehta et al., 2008; Trepka et al., 2007) and higher uptake 
reported in community clinic-based (Morrill, Shrestha, & Grant, 2005) and Australian 
(Grebely et al., 2008) studies. In this sample, an impressive 21 of 35 (60%) participants who 
reported that they sought treatment from a healthcare provider ended up receiving treatment 
for HCV. This might suggest that individual-level barriers overshadow those at the physician 
level, given that although many participants made the initial step of contacting a provider for 
HCV-related follow-up, relatively few described themselves as seeking treatment through 
the encounter. This could also perhaps reflect the reputation of severe side effects and 
middling efficacy among the older interferon-based treatments available at the time data 
were collected.
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As in prior research (Denniston, Klevens, McQuillan, & Jiles, 2012; Stepanova, Kanwal, El-
Serag, & Younossi, 2011), health insurance coverage was a robust predictor of making 
contact for medical follow-up in this rural sample. Unfortunately, however, nearly 70% of 
the cohort was uninsured throughout the study period, implicating lack of insurance 
coverage and most likely, healthcare costs as major barriers to HCV care among rural 
Appalachians who use drugs. However, given the recent, but uncertain expansion of health 
insurance coverage in the United States (Gallup Well-Being, 2014; U.S. Department of 
Health and Human Services, 2014) and in Kentucky in particular (Brammer, 2014), coupled 
with rapidly evolving cost and efficacy of HCV pharmacotherapy, further study of this 
perennially volatile factor among rural PWID is needed.
Concordant with other research reporting correlation between interest in IDU cessation and 
HCV treatment (Strathdee et al., 2005), lifetime history of SUD treatment increased the 
probability of making contact for medical follow-up in this sample. However, time-variant 
reporting of SUD treatment within the last six months did not reflect this association, and 
somewhat surprisingly, recent legal methadone use (i.e., OST) decreased the odds of 
contacting a provider. This suggests that while past treatment for SUD may boost healthcare 
engagement after HCV screening in this population, contemporaneous SUD treatment and 
OST do not seem to directly promote HCV-related healthcare under current conditions, 
echoing the negative association reported by Grebely et al. (2011) among Australian PWID. 
However, it is also possible that in this study HCV-positive participants already aware of 
their HCV status had been referred to medical evaluation through their OST prescriber prior 
to study enrollment, artificially decreasing these individuals’ report of provider contact after 
T&C during the study. Nonetheless, the possibility that legal methadone use did not increase 
the probability of seeking out HCV-related medical care among seropositive individuals is 
concerning given what few harm reduction services are currently available in Central 
Appalachia and the effectiveness of integrated services for PWID demonstrated in other 
settings (Grebely et al., 2007; Grebely et al., 2010; Masson et al., 2013). Finally, as 
suggested in previous research (McGibbon et al., 2013; McGowan et al., 2013; Morrill et al., 
2005; Treloar, Newland, Rance, & Hopwood, 2010), there may also be provider- and/or 
system-level biases against treating HCV among opioid-dependent individuals receiving 
OST, particularly PWID. In any case, this finding reinforces the notion that harm reduction, 
SUD treatment, and HCV-related healthcare services are not well-integrated in rural Central 
Appalachia.
Two characteristics promoting contact of a healthcare provider for HCV follow-up in this 
sample have not been reported similar prior studies. First, access to the internet nearly 
doubled the likelihood of healthcare contact during the subsequent study interval. This 
association suggests that there could be a protective benefit in online access to information 
regarding the health impacts and/or treatment options for HCV. In light of past research 
describing the potential of internet access to increase patient knowledge level, facilitate 
dissemination of health information, and promote “patient activism” (Magnezi et al., 2014; 
Pew Internet & American Life Project, 2010; Stevenson, Kerr, Murray, & Nazareth, 2007)—
including among patients with HIV (Kalichman et al., 2002) and other chronic diseases such 
as cancer (Basch, Thaler, Shi, Yakren, & Schrag, 2004)—it is possible that similar 
mechanisms act on HCV-seropositive individuals. Furthermore, this finding is of particular 
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interest given the ongoing scarcity of internet access in the rural Central Appalachian region 
sampled here (Lawrence et al., 2015).
Another unexpected association promoting contact for medical follow-up was observed 
among recent marijuana users in this rural cohort. One study from the interferon/ribavirin 
era reported significant improvements in both treatment retention and efficacy among recent 
marijuana users (Sylvestre, 2002; Sylvestre, Clements, & Malibu, 2006), but no other 
protective associations have been reported with regard to marijuana use and promotion of 
HCV-related care. One possible explanation is that rural PWID interested in ceasing IDU but 
with poor access to addiction treatment services might substitute marijuana for prescription 
opioids or other drugs of injection, although this hypothesis has not been systematically 
assessed. Further investigation of marijuana use in this population would be beneficial, 
particularly as daily cannabis use may accelerate progression of hepatic disease among 
individuals with chronic HCV (Hezode et al., 2008; Mallat, Hezode, & Lotersztajn, 2008).
Finally, two psychiatric measures were independently associated with making contact for 
medical follow-up and are of particular interest given the well-established role of mental 
health comorbidity in determining HCV treatment eligibility (AASLD-IDSA, 2016) and 
frequent psychosocial impairment among individuals with chronic HCV (Fireman, Indest, 
Blackwell, Whitehead, & Hauser, 2005; Modabbernia, Poustchi, & Malekzadeh, 2013). 
Depressive symptomatology is a common barrier to healthcare engagement in general, 
including among individuals with HCV (Nguyen, Dore, Kaldor, & Hellard, 2007; Treloar et 
al., 2010), so the negative association with MDD observed here is not unexpected. 
Moreover, depressive disorders are frequently comorbid with HCV, and depressed 
individuals are more likely to report symptoms, fatigue, and other impacts resulting from 
chronic infection (Dwight et al., 2000; Golden, O’Dwyer, & Conroy, 2005). By contrast, 
participants meeting criteria for GAD displayed a strong positive association with making 
contact for follow-up in this sample, although few prior studies have investigated HCV-
related care in the context of anxiety disorders. No differences with regard to the adverse 
impacts of illness were reported among HCV-positive patients in one study (Golden et al., 
2005), despite frequent associations between anxiety disorders and chronic HCV (el-Serag, 
Kunik, Richardson, & Rabeneck, 2002). While no previous studies have reported an 
association between GAD and HCV-related healthcare engagement, it seems intuitive that 
individuals more likely to experience anxiety after HCV status disclosure and counseling are 
also more inclined to seek out medical care for a potentially fatal condition such as chronic 
HCV. Additional study could clarify the relationship between psychiatric comorbidity and 
healthcare-seeking behavior among people who use and inject drugs, particularly in the 
setting of highly prevalent non-medical prescription opioid use.
Although this study provides insight into the initial steps of HCV-related medical assessment 
and treatment engagement in a rarely studied population, there are limitations to consider. 
First, the study survey asked specifically about contacting a healthcare provider for 
recommended follow-up testing and evaluation, rather than receipt of such follow-up, which 
could explain the relatively high rate of HCV-related healthcare engagement reported by 
participants in this sample. However, it should be noted that given the relatively recent 
legalization of SEPs in Kentucky with associated disease screening programs, HCV status 
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awareness and associated post-test counseling with recommendations to pursue medical 
follow-up are likely to rise; therefore, understanding the initial step of HCV-related 
healthcare engagement following T&C is of utmost importance. Next, the proportion of 
participants reporting treatment-seeking and receipt may be depressed relative to present-day 
conditions, given that data collection occurred prior to the advent of dramatically more 
efficacious, better tolerated, and attenuated direct-acting antiviral regimens (Li & De Clercq, 
2017), as outlined previously. Finally, as with most research on substance-using populations, 
the analyses presented here relied on self-reported data, which can be subject to under-
reporting or over-reporting due to social desirability and recall biases, including the primary 
outcome variable. However, recall bias is expected to be minimized by the use of time-
varying measures pertaining to the prior six months or less, and previous studies have found 
self-reported behavior from people who use and inject drugs to be a reliable source of data 
(Darke, 1998; Kokkevi, Richardson, Palermou, & Leventakou, 1997).
In summary, additional intervention and research in rural populations characterized by high 
HCV transmission risk and complex barriers to initiation and engagement in HCV-related 
care are warranted. For example, intervening at the time of T&C with active referrals to 
HCV-related follow-up care at the time of screening might present a promising and effective 
means of increasing the proportion of treatment-eligible rural patients reaching points 
further downstream in the cascade of HCV-related medical care. Such interventional study 
might present particular benefit to individuals receiving disease screening and/or harm 
reduction services such as OST and SEPs, which present fleeting opportunities for rural 
PWID to be linked to HCV-related care in resource-poor regions with relatively scarce 
medical and social support resources. However, the lack of HCV treatment providers in 
many rural areas, and Appalachian Kentucky in particular, is a major barrier. Based on 
research in urban settings, integrated programs offering psychiatric, SUD, harm reduction, 
and medical care targeted to underserved populations characterized by poor access to 
preventive resources would seem to promise highest likelihood of benefit. In addition, it 
would be interesting to evaluate HCV-related healthcare contact, treatment-seeking, and 
treatment receipt in the era of newer, highly efficacious, and substantially more tolerable 
direct-acting antiviral agents, as well as increased health insurance coverage and more 
widely available harm reduction services in this long-underserved population.
Acknowledgments
This research was supported by the National Institutes of Health, National Institutes on Drug Abuse (grant numbers 
R01DA024598 and R01DA033862 awarded to J.R. Havens). D.B. Stephens was supported by NIH T32 training 
grant TL1RR033172.
References
AASLD-IDSA. Recommendations for Testing, Managing, and Treating Hepatitis C. 2016. Retrieved 
from http://www.hcvguidelines.org
Allison PD. Discrete-time methods for the analysis of event histories. Sociological Methodology. 
1982; 13(1):61–98.
Appalachian Regional Commission. An analysis of mental health and substance abuse disparities & 
access to treatment services in the Appalachian region. Appalachian Regional Commission. 2008. 
Retrieved from http://www.arc.gov/research/researchreportdetails.asp?REPORT_ID=71
Stephens et al. Page 10
Int J Drug Policy. Author manuscript; available in PMC 2018 September 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Astell-Burt T, Flowerdew R, Boyle PJ, Dillon JF. Does geographic access to primary healthcare 
influence the detection of hepatitis C? Soc Sci Med. 2011; 72(9):1472–1481. [PubMed: 21481509] 
Basch EM, Thaler HT, Shi W, Yakren S, Schrag D. Use of information resources by patients with 
cancer and their companions. Cancer. 2004; 100(11):2476–2483. [PubMed: 15160355] 
Birkhead GS, Klein SJ, Candelas AR, O’Connell DA, Rothman JR, Feldman IS, Tsui DS, Cotroneo 
RA, Flanigan CA. Integrating multiple programme and policy approaches to hepatitis C prevention 
and care for injection drug users: a comprehensive approach. Int J Drug Policy. 2007; 18(5):417–
425. [PubMed: 17854731] 
Brammer, J. [April 22, 2014] Beshear says more than 413,000 Kentuckians signed up for health care in 
state exchange. Lexington Herald-Leader. 2014. Retrieved from http://www.kentucky.com/
2014/04/22/3207241/beshear-says-more-than-413000.html
Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis 
C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and 
Prevention. MMWR Recomm Rep. 1998; 47(RR-19):1–39.
Centers for Disease Control and Prevention. Viral Hepatitis Surveillance - United States, 2014. 2016. 
Retrieved from https://www.cdc.gov/hepatitis/statistics/2014surveillance/index.htm
Cullen W, Stanley J, Langton D, Kelly Y, Bury G. Management of hepatitis C among drug users 
attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general 
practice initiative. Eur J Gen Pract. 2007; 13(1):5–12. [PubMed: 17366287] 
Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998; 51(3):253–
263. discussion 267–258. [PubMed: 9787998] 
Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of 
hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National 
Health and Nutrition Examination Survey 2001–2008. Hepatology. 2012; 55(6):1652–1661. 
[PubMed: 22213025] 
Department for Public Health. HIV Prevention Program. 2015. Retrieved from http://
chfs.ky.gov/dph/epi/HIVAIDS/prevention.htm
Des Jarlais DC, Nugent A, Solberg A, Feelemyer J, Mermin J, Holtzman D. Syringe Service Programs 
for Persons Who Inject Drugs in Urban, Suburban, and Rural Areas - United States, 2013. MMWR 
Morb Mortal Wkly Rep. 2015; 64(48):1337–1341. [PubMed: 26655918] 
Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ. Depression, fatigue, 
and functional disability in patients with chronic hepatitis C. J Psychosom Res. 2000; 49(5):311–
317. [PubMed: 11164055] 
el-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis 
C infection. Gastroenterology. 2002; 123(2):476–482. [PubMed: 12145801] 
Environmental Systems Research Institute. ESRI Data and Maps 10 (StreetMap North America). 
Redlands, CA: 2010. 
Fireman M, Indest DW, Blackwell A, Whitehead AJ, Hauser P. Addressing tri-morbidity (hepatitis C, 
psychiatric disorders, and substance use): the importance of routine mental health screening as a 
component of a comanagement model of care. Clin Infect Dis. 2005; (40 Suppl 5):S286–291. 
[PubMed: 15768336] 
Gallup Well-Being. In U.S., Uninsured Rate Sinks to 13.4% in Second Quarter. 2014. Retrieved from 
http://www.gallup.com/poll/172403/uninsured-rate-sinks-second-quarter.aspx
Golden J, O’Dwyer AM, Conroy RM. Depression and anxiety in patients with hepatitis C: prevalence, 
detection rates and risk factors. Gen Hosp Psychiatry. 2005; 27(6):431–438. [PubMed: 16271658] 
Grebely J, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Phung N, Weltman MD, Day CA, Treloar 
C, Bath N, Haber PS, Dore GJ. Treatment for hepatitis C virus infection among people who inject 
drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. 
Addiction. 2016; 111(2):311–319. [PubMed: 26451534] 
Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? Antiviral 
Res. 2014; 104:62–72. [PubMed: 24468275] 
Grebely J, Genoway K, Khara M, Duncan F, Viljoen M, Elliott D, Raffa JD, DeVlaming S, Conway B. 
Treatment uptake and outcomes among current and former injection drug users receiving directly 
Stephens et al. Page 11
Int J Drug Policy. Author manuscript; available in PMC 2018 September 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus 
infection. Int J Drug Policy. 2007; 18(5):437–443. [PubMed: 17854734] 
Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, Kalousek K, Duncan F, Tyndall 
MW, Fraser C, Conway B, Fischer B. Barriers associated with the treatment of hepatitis C virus 
infection among illicit drug users. Drug Alcohol Depend. 2008; 93(1–2):141–147. [PubMed: 
17997050] 
Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, Gallagher L, Storms M, Raffa JD, 
DeVlaming S, Duncan F, Conway B. Optimizing assessment and treatment for hepatitis C virus 
infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. 
Eur J Gastroenterol Hepatol. 2010; 22(3):270–277. [PubMed: 20425880] 
Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, Fischer B, Tyndall MW. Low uptake of treatment for 
hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat. 
2009; 16(5):352–358. [PubMed: 19226330] 
Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld 
JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer 
M, Taylor LE, Dore GJ. Recommendations for the management of hepatitis C virus infection 
among people who inject drugs. Int J Drug Policy. 2015; 26(10):1028–1038. [PubMed: 26282715] 
Havens JR, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA. Individual and network 
factors associated with prevalent hepatitis C infection among rural Appalachian injection drug 
users. Am J Public Health. 2013; 103(1):e44–52. DOI: 10.2105/AJPH.2012.300874
Heckathorn D. Respondent-driven sampling: A new approach to the study of hidden populations. 
Social Problems. 1997; 44(2):174–199.
Hezode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, Medkour F, 
Pawlostky JM, Lotersztajn S, Mallat A. Daily cannabis use: a novel risk factor of steatosis severity 
in patients with chronic hepatitis C. Gastroenterology. 2008; 134(2):432–439. [PubMed: 
18242211] 
Hosmer, D., Lemeshow, S. Applied Logistic Regression. New York: Wiley; 1989. 
Kalichman SC, Weinhardt L, Benotsch E, DiFonzo K, Luke W, Austin J. Internet access and Internet 
use for health information among people living with HIV-AIDS. Patient Educ Couns. 2002; 46(2):
109–116. [PubMed: 11867240] 
Kentucky Legislative Research Commission. [June 20, 2005] Sale and disposal of hypodermic 
syringes or needles, KRS 217.177. 2005. Retrieved from http://www.lrc.ky.gov/krs/217-00/177.pdf
Kokkevi A, Richardson C, Palermou B, Leventakou V. Reliability of drug dependents’ self-reports. 
Drug Alcohol Depend. 1997; 45(1–2):55–61. [PubMed: 9179507] 
Lawrence, S., Oliver, L., Hogan, M., VanLear, S., Baller, J., Horrigan, J., Johnson, M., Patterson, JS., 
Stelfox, A., Watts, D. Program Evaluation of the Appalachian Regional Commission’s 
Telecommunications and Technology Projects: FY 2004–FY 2010. 2015. Retrieved from https://
www.arc.gov/research/researchreportdetails.asp?REPORT_ID=120
Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. 
Antiviral Res. 2017
Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Memish ZA. A comparative risk 
assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 
21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. 
Lancet. 2012; 380(9859):2224–2260. [PubMed: 23245609] 
Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality 
from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012; 156(4):
271–278. [PubMed: 22351712] 
Magnezi R, Grosberg D, Novikov I, Ziv A, Shani M, Freedman LS. Characteristics of patients seeking 
health information online via social health networks versus general Internet sites: a comparative 
study. Inform Health Soc Care. 2014
Mallat A, Hezode C, Lotersztajn S. Environmental factors as disease accelerators during chronic 
hepatitis C. J Hepatol. 2008; 48(4):657–665. [PubMed: 18279998] 
Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, 
Goldberg DJ, Dore GJ, Hickman M. Hepatitis C virus treatment for prevention among people who 
Stephens et al. Page 12
Int J Drug Policy. Author manuscript; available in PMC 2018 September 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013; 
58(5):1598–1609. [PubMed: 23553643] 
Masson CL, Delucchi KL, McKnight C, Hettema J, Khalili M, Min A, Jordan AE, Pepper N, Hall J, 
Hengl NS, Young C, Shopshire MS, Manuel JK, Coffin L, Hammer H, Shapiro B, Seewald RM, 
Bodenheimer HC Jr, Sorensen JL, Des Jarlais DC, Perlman DC. A randomized trial of a hepatitis 
care coordination model in methadone maintenance treatment. Am J Public Health. 2013; 
103(10):e81–88.
McGibbon E, Bornschlegel K, Balter S. Half a diagnosis: gap in confirming infection among hepatitis 
C antibody-positive patients. Am J Med. 2013; 126(8):718–722. [PubMed: 23786667] 
McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, Poordad F, Afdhal N, Zeuzem 
S, Piratvisuth T, Marcellin P, Fried MW. A global view of hepatitis C: physician knowledge, 
opinions, and perceived barriers to care. Hepatology. 2013; 57(4):1325–1332. [PubMed: 
23315914] 
Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL. 
Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008; 
33(3):126–133. [PubMed: 18165889] 
Modabbernia A, Poustchi H, Malekzadeh R. Neuropsychiatric and psychosocial issues of patients with 
hepatitis C infection: a selective literature review. Hepat Mon. 2013; 13(1):e8340. [PubMed: 
23550100] 
Monnet E, Ramee C, Minello A, Jooste V, Carel D, Di Martino V. Socioeconomic context, distance to 
primary care and detection of hepatitis C: a French population-based study. Soc Sci Med. 2008; 
66(5):1046–1056. [PubMed: 18164525] 
Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and 
system factors. J Gen Intern Med. 2005; 20(8):754–758. [PubMed: 16050887] 
Mravcik V, Strada L, Stolfa J, Bencko V, Groshkova T, Reimer J, Schulte B. Factors associated with 
uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature 
review. Patient Prefer Adherence. 2013; 7:1067–1075. [PubMed: 24204126] 
Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global 
epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic 
reviews. Lancet. 2011; 378(9791):571–583. [PubMed: 21802134] 
Nguyen OK, Dore GJ, Kaldor JM, Hellard ME. Recruitment and follow-up of injecting drug users in 
the setting of early hepatitis C treatment: insights from the ATAHC study. Int J Drug Policy. 2007; 
18(5):447–451. [PubMed: 17854736] 
Pew Internet & American Life Project. Chronic Disease and the Internet. 2010. Retrieved from http://
www.pewinternet.org/files/old-media/Files/Reports/2010/PIP_Chronic_Disease_with_topline.pdf
Rehermann B. HCV in 2015: Advances in hepatitis C research and treatment. Nat Rev Gastroenterol 
Hepatol. 2016; 13(2):70–72. [PubMed: 26790365] 
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar 
GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation 
of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 
(59 Suppl 20):22–33. quiz 34–57. 
Singer JD, Willett JB. It’s about time: Using discrete-time survival analysis to study duration and the 
timing of events. Journal of Educational and Behavioral Statistics. 1993; 18(2):155–195.
Singer, JD., Willett, JB. Applied Longitudinal Data Analysis: Modeling Change and Event 
Occurrence. New York: Oxford University Press; 2003. 
Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, Baack B, Rein 
DB, Patel N, Alter M, Yartel A, Ward JW. Recommendations for the identification of chronic 
hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012; 
61(RR-4):1–32.
Spradling PR, Tong X, Rupp L, Moorman AC, Lu M, Teshale EH, Gordon SC, Vijayadeva V, 
Boscarino JA, Schmidt MA, Holmberg SD. Trends in HCV RNA testing among HCV antibody 
positive persons in care, 2003–2010. Clin Infect Dis. 2014; 59(7):976–81. [PubMed: 24991025] 
Stensland, JMC., Sutton, J. An Analysis of the Financial Conditions of Health Care Institutions in the 
Appalachian Region and their Economic Impacts. Washington DC: 2002. 
Stephens et al. Page 13
Int J Drug Policy. Author manuscript; available in PMC 2018 September 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of 
hepatitis C patients: analysis of population-based data from the United States. Hepatology. 2011; 
53(3):737–745. [PubMed: 21319199] 
Stevenson FA, Kerr C, Murray E, Nazareth I. Information from the Internet and the doctor-patient 
relationship: the patient perspective--a qualitative study. BMC Fam Pract. 2007; 8:47. [PubMed: 
17705836] 
Stoove MA, Gifford SM, Dore GJ. The impact of injecting drug use status on hepatitis C-related 
referral and treatment. Drug Alcohol Depend. 2005; 77(1):81–86. [PubMed: 15607844] 
Strathdee SA, Latka M, Campbell J, O’Driscoll PT, Golub ET, Kapadia F, Pollini RA, Garfein RS, 
Thomas DL, Hagan H. Factors associated with interest in initiating treatment for hepatitis C Virus 
(HCV) infection among young HCV-infected injection drug users. Clin Infect Dis. 2005; (40 Suppl 
5):S304–312. [PubMed: 15768339] 
Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug 
Alcohol Depend. 2002; 67(2):117–123. [PubMed: 12095661] 
Sylvestre DL, Clements BJ, Malibu Y. Cannabis use improves retention and virological outcomes in 
patients treated for hepatitis C. Eur J Gastroenterol Hepatol. 2006; 18(10):1057–1063. [PubMed: 
16957511] 
Treloar C, Hull P, Dore GJ, Grebely J. Knowledge and barriers associated with assessment and 
treatment for hepatitis C virus infection among people who inject drugs. Drug Alcohol Rev. 2012; 
31(7):918–924. [PubMed: 22612899] 
Treloar C, Newland J, Rance J, Hopwood M. Uptake and delivery of hepatitis C treatment in opiate 
substitution treatment: perceptions of clients and health professionals. J Viral Hepat. 2010; 17(12):
839–844. [PubMed: 20070504] 
Trepka MJ, Zhang G, Leguen F, Obiaja K, Malow RM, De La Rosa M. Benefits and adverse effects of 
hepatitis C screening: early results of a screening program. J Public Health Manag Pract. 2007; 
13(3):263–269. [PubMed: 17435493] 
U.S. Department of Health and Human Services. Profiles of Affordable Care Act Coverage Expansion 
Enrollment for Medicaid/CHIP and the Health Insurance Marketplace, 10-1-2013 to 3-31-2014. 
2014. Retrieved from http://aspe.hhs.gov/health/reports/2014/MarketPlaceEnrollment/Apr2014/
Marketplace_StateSum.cfm
US Food and Drug Administration. Home Access® Hepatitis C Check and Hepatitis C Check Express 
Summary of Safety and Effectivess. 1999. Retrieved from http://www.accessdata.fda.gov/
cdrh_docs/pdf/P980046b.pdf
Volz, E., Wejnert, C., Cameron, C., Spiller, M., Barash, V., Degani, I., Heckathorn, D. Respondent-
driven Sampling Analysis Tool (RDSAT) Version 7.1. Ithaca, NY: Cornell University; 2012. 
Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, EMCDDA DRID Group. Hatzakis 
A, Prins M, Vickerman P, Lazarus JV, Hope VD, Mathei C. Hepatitis C virus infection 
epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up 
treatment and prevention. PLoS One. 2014; 9(7):e103345. [PubMed: 25068274] 
Young AM, Jonas AB, Havens JR. Social networks and HCV viraemia in anti-HCV-positive rural drug 
users. Epidemiol Infect. 2013; 141(2):402–411. [PubMed: 22717190] 
Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, Serrecchia J, 
Blankenship S, Ward JW, Holtzman D. Increases in hepatitis C virus infection related to injection 
drug use among persons aged </=30 years - Kentucky, Tennessee, Virginia, and West Virginia, 
2006–2012. MMWR Morb Mortal Wkly Rep. 2015; 64(17):453–458. [PubMed: 25950251] 
Stephens et al. Page 14
Int J Drug Policy. Author manuscript; available in PMC 2018 September 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 1. 
RDS-adjusted hazard functions depicting conditional probability of contacting a healthcare 
provider for medical follow-up after HCV-positive serotesting and post-test counseling. No 
difference was detected between the fully discrete and linear models for the main effect of 
time (p=0.68). BIC=Bayesian information criterion.
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Table 1
Description of HCV medical care-related behaviors and treatment uptake after positive serotest and counseling 
(N=254)
Aspect of HCV care Sample total
n (%)
Population estimate
% (95% CI)
Contacted provider for follow-up evaluation 150 (59.1) 51.8 (44.5–58.9)
Endorsed seeking treatment for HCV 35 (13.8) 12.4 (8.4–8.1)
Received treatment for HCV 21 (8.3) 7.8 (4.5–13.1)
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Table 2
Description of sample and bivariate associations with contacting a healthcare provider for follow-up after 
HCV-positive serotest and counseling (N=254)1
Characteristic Sample total
n (%)
Odds
Ratio
95% CI p-
value
Time-invariant
  Male 152 (59.8) 0.73 0.44 – 1.20 0.209
  White 241 (94.9) 0.92 0.32 – 2.66 0.874
  Age (years) - mean (SD) 33.1 (8.0) 0.99 0.96 – 1.02 0.213
  Heterosexual 23 (9.1) 0.58 0.32 – 2.66 0.198
  Married 60 (23.6) 0.73 0.42 – 1.27 0.270
  Number of dependents - mean (SD) 0.9 (1.4) 1.03 0.86 – 1.25 0.716
  Education (months) - mean (SD) 137.3 (29.3) 1.00 0.99 – 1.01 0.454
  Monthly income (US $) - mean (SD) 1283.6 (1949.6) 1.01 0.99 – 1.01 0.284
  % of income legal - mean (SD) 93 .8 (19.8) 0.98 0.97 – 1.00 0.036
  Most often unemployed (last 3 years) 78 (30.7) 0.95 0.56 – 1.59 0.832
  Driver’s license and access to vehicle 92 (36.2) 0.98 0.58 – 1.64 0.930
  Major depressive disorder 68 (26.8) 0.95 0.55 – 1.62 0.839
  Generalized anxiety disorder 73 (28.7) 1.78 1.04 – 3.05 0.036
  Antisocial personality disorder 76 (29.9) 0.86 0.51 – 1.47 0.589
  Post-traumatic stress disorder 35 (13.8) 0.89 0.44 – 1.83 0.754
  Incident HCV during SNAP 30 (11.8) 0.88 0.37 – 2.08 0.770
  Aware of HCV+ status prior to study 68 (26.8) 1.45 0.84 – 2.50 0.185
  ≥5 of 6 general HCV questions correct 234 (92.1) 1.56 0.62 – 3.94 0.343
  Aware of HCV treatment 218 (85.8) 1.22 0.63 – 2.36 0.558
Time-varying
  Health insurance coverage2 80 (31.5) 1.97 1.19 – 3.27 0.008
  “Good” or “excellent” health status 164 (64.6) 0.90 0.56 – 1.56 0.679
  Chronic medical condition 106 (41.7) 1.11 0.67 – 1.83 0.691
  Taking legally prescribed medication 86 (33.9) 1.44 0.81 – 2.56 0.216
  Receiving government benefits for disability 36 (14.2) 1.97 0.99 – 3.92 0.055
  Access to internet 151 (59.5) 1.88 1.19 – 2.97 0.007
  Incarceration (last 30 days) 68 (26.8) 1.18 0.66 – 2.11 0.574
  Distance to hospital (km) - mean (SD)3 11.3 (10.2) 0.99 0.96 – 1.01 0.246
  Social support out-degree - mean (SD) 2.0 (1.2) 1.12 0.93 – 1.34 0.222
Lifetime behavior (reported at time of HCV+ test)
  Received substance abuse treatment 152 (59.8) 1.96 1.20 – 3.20 0.008
  Incarceration 222 (87.4) 1.35 0.62 – 2.94 0.450
  Drug overdose 72 (28.4) 1.55 0.89 – 2.67 0.119
  Injection drug use 240 (94.5) 1.88 0.60 – 6.11 0.293
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Characteristic Sample total
n (%)
Odds
Ratio
95% CI p-
value
  Heroin use 107 (42.1) 1.13 0.70 – 1.83 0.621
  Illicit methadone use 240 (94.5) 0.32 0.13 – 0.76 0.010
  Legal methadone use 63 (24.8) 0.91 0.53 – 1.56 0.733
  Illicit buprenophine use 183 (72.1) 1.05 0.62 – 1.76 0.868
  Legal buprenorphine use 30 (11.8) 1.53 0.69 – 3.41 0.295
  Illicit OxyContin® use4 249 (98.0) 2.44 0.34 – 17.42 0.374
  Other prescription opioid use 245 (96.5) 0.31 0.06 – 1.67 0.172
  Sedative, hypnotic, or tranquilizer use 238 (93.7) 0.58 0.26 – 1.33 0.199
  Barbiturate use 43 (16.9) 0.83 0.45 – 1.51 0.537
  Crack use 197 (77.6) 0.92 0.47 – 1.82 0.819
  Cocaine use 240 (94.5) 0.64 0.23 – 1.82 0.405
  Methamphetamine use 113 (44.5) 0.87 0.54 – 1.44 0.630
  Oral amphetamine use 86 (33.9) 0.83 0.49 – 1.40 0.480
  Marijuana use 247 (97.2) 0.34 0.08 – 1.39 0.133
  Hallucinogen use 139 (54.7) 1.01 0.62 – 1.65 0.954
  Polysubstance use 246 (96.9) 0.84 0.14 – 4.92 0.845
Recent behavior (last six months)
  Substance abuse treatment 42 (16.5) 1.01 0.59 – 1.74 0.973
  Drug overdose 10 (3.9) 1.63 0.46 – 5.74 0.446
  Alcohol use to intoxication 128 (50.4) 1.02 0.63 – 1.64 0.946
  Injection drug use 170 (66.9) 0.95 0.59 – 1.52 0.818
  Sharing of any IDU equipment 72 (28.4) 1.08 0.59 – 1.98 0.803
  Heroin use 12 (4.7) 2.19 0.65 – 7.43 0.208
  Illicit methadone use 144 (56.7) 1.48 0.93 – 2.35 0.100
  Legal methadone use 9 (3.5) 0.44 0.10 – 1.95 0.277
  Illicit buprenorphine use 130 (51.2) 1.55 0.97 – 2.50 0.068
  Legal buprenorphine use 23 (9.1) 1.69 0.66 – 4.34 0.275
  OxyContin® use3 194 (76.4) 1.35 0.80 – 2.28 0.258
  Other prescription opioid use 201 (79.1) 1.22 0.75 – 1.98 0.431
  Sedative, hypnotic or tranquilizer use 195 (76.8) 1.43 0.86 – 2.39 0.166
  Barbiturate use 8 (3.2) 2.89 0.93 – 8.99 0.066
  Crack use 40 (15.8) 1.67 0.85 – 3.26 0.134
  Cocaine use 80 (31.5) 1.05 0.61 – 1.82 0.849
  Methamphetamine use 20 (7.9) 1.60 0.62 – 4.15 0.329
  Oral amphetamine use 38 (15.0) 1.51 0.74 – 3.05 0.257
  Marijuana use 170 (66.9) 1.72 1.07 – 2.78 0.026
  Hallucinogen use 5 (2.0) 1.38 0.18 – 10.70 0.756
  Polysubstance use 225 (88.6) 1.35 0.76 – 2.40 0.310
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1
Adjusted for respondent-driven sampling
2
Private insurance, Medicaid, or Medicare
3
n=244, excluding 10 participants who moved from study area
4
Includes original and abuse-deterrent formulations of OxyContin®
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Table 4
Predictors of contacting a healthcare provider for follow-up after HCV-positive serotest and counseling: linear 
time model (N=254)1
Variable Adjusted
Odds Ratio
95% Confidence
Interval
p-value
Time (per study interval) 0.59 0.43 – 0.80 0.001
Previous HCV+ status awareness 1.70 0.93 – 3.08 0.083
Health insurance2 2.06 1.20 – 3.53 0.009
Access to internet 1.83 1.15 – 2.92 0.011
Major depressive disorder 0.47 0.23 – 0.96 0.039
Generalized anxiety disorder 2.63 1.33 – 5.18 0.005
Ever received substance abuse treatment 1.67 1.01 – 2.75 0.045
Ever used illicit methadone 0.33 0.14 – 0.82 0.016
Legal methadone use (last 6 months) 0.21 0.05 – 0.90 0.035
Marijuana use (last 6 months) 1.76 1.09 – 2.84 0.021
1
Discrete-time survival analysis adjusted for RDS
2
Includes private insurance, Medicaid, or Medicare reported at onset of study interval
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